Q-omics provides the consensus-scored KNDC1 profile across patient tissues and cancer cell-line models. KNDC1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, KNDC1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, KNDC1 RNA expression shows 16,201 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, KIRC, and LSCC as cancer lineages where KNDC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KNDC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KNDC1 survival associations across molecular data types. KNDC1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KNDC1 RNA expression–survival associations across cancer types. High KNDC1 expression shows unfavorable associations in COAD, LUSC and LAML, but favorable associations in MESO, ACC and SCLC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for KNDC1 RNA expression.
This table summarizes KNDC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KNDC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KNDC1 shows lower tumor expression in LUSC, LUAD and UCEC and higher tumor expression in KIRC, KICH and BRCA. The KIRC box plot shows higher KNDC1 RNA expression in tumor versus normal tissue (log2 FC = +0.845, t-test p < 0.001).
This table shows molecular features associated with KNDC1 in patient tissues and cancer cell lines. In patient samples, KNDC1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KNDC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
